Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy. Issue 11 (June 2016)
- Record Type:
- Journal Article
- Title:
- Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy. Issue 11 (June 2016)
- Main Title:
- Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy
- Authors:
- Antonângelo, Leila
Tuma, Taila
Fabro, Alexandre
Acencio, Milena
Terra, Ricardo
Parra, Edwin
Vargas, Francisco
Takagaki, Teresa
Capelozzi, Vera - Abstract:
- Inhibitors of DNA binding/inhibitors of differentiation (Id) protein family have been shown to be involved in carcinogenesis. However, the roles of Id during lung adenocarcinoma (ADC) progression remain unclear. Eighty-eight ADC samples were evaluated for Id-1, 2, 3 level and angiogenesis (CD 34 and VEGF microvessel density) by immunohistochemistry and morphometry. The impact of these markers was tested on follow-up until death or recurrence. A significant difference between tumor and normal tissue was found for Id-1, 2, 3 expression ( P < 0.01). In addition, high levels of nuclear Id-1 were associated with higher angiogenesis in the tumor stroma ( P < 0.01). Equally significant was the association between patients in T1 -stage and low cytoplasmic Id-2, as well as patients in stage-IIb and low Id-3. High cytoplasm Id-3 expression was also directly associated to lymph nodes metastasis ( P = 0.05). Patients at stages I to III, with low Id-1 and Id-3 cytoplasm histoscores showed significant long metastasis-free survival time than those with high Id-1 or Id-3 expression ( P = 0.04). Furthermore, high MVD-CD34 and MVD-VEGF expression were associated with short recurrence-free survival compared to low MVD-CD34 and MVD-VEGF expressions ( P = 0.04). Cox model analyses controlled for age, lymph node metastasis, and adjuvant treatments showed that nuclear Id-1, cytoplasmic Id-3, and MVD-CD34 were significantly associated with survival time. Median score for nuclear Id-1 andInhibitors of DNA binding/inhibitors of differentiation (Id) protein family have been shown to be involved in carcinogenesis. However, the roles of Id during lung adenocarcinoma (ADC) progression remain unclear. Eighty-eight ADC samples were evaluated for Id-1, 2, 3 level and angiogenesis (CD 34 and VEGF microvessel density) by immunohistochemistry and morphometry. The impact of these markers was tested on follow-up until death or recurrence. A significant difference between tumor and normal tissue was found for Id-1, 2, 3 expression ( P < 0.01). In addition, high levels of nuclear Id-1 were associated with higher angiogenesis in the tumor stroma ( P < 0.01). Equally significant was the association between patients in T1 -stage and low cytoplasmic Id-2, as well as patients in stage-IIb and low Id-3. High cytoplasm Id-3 expression was also directly associated to lymph nodes metastasis ( P = 0.05). Patients at stages I to III, with low Id-1 and Id-3 cytoplasm histoscores showed significant long metastasis-free survival time than those with high Id-1 or Id-3 expression ( P = 0.04). Furthermore, high MVD-CD34 and MVD-VEGF expression were associated with short recurrence-free survival compared to low MVD-CD34 and MVD-VEGF expressions ( P = 0.04). Cox model analyses controlled for age, lymph node metastasis, and adjuvant treatments showed that nuclear Id-1, cytoplasmic Id-3, and MVD-CD34 were significantly associated with survival time. Median score for nuclear Id-1 and cytoplasmic Id-3 divided patients in two groups, being that those with increased Id-1 and Id-3 presented higher risk of death. Ids showed an independent prognostic value in patients with lung ADC, regardless of disease stage. Id-1 and Id-3 should be considered new target candidates in the development of personalized therapy in lung ADC. … (more)
- Is Part Of:
- Experimental biology and medicine. Volume 241:Issue 11(2016)
- Journal:
- Experimental biology and medicine
- Issue:
- Volume 241:Issue 11(2016)
- Issue Display:
- Volume 241, Issue 11 (2016)
- Year:
- 2016
- Volume:
- 241
- Issue:
- 11
- Issue Sort Value:
- 2016-0241-0011-0000
- Page Start:
- 1159
- Page End:
- 1168
- Publication Date:
- 2016-06
- Subjects:
- Lung adenocarcinoma -- inhibitors of DNA binding/inhibitors of differentiation -- angiogenesis -- immunohistochemistry -- morphometry -- prognosis
Physiology -- Periodicals
Biology, Experimental -- Periodicals
Medicine, Experimental -- Periodicals
610.72 - Journal URLs:
- http://ebm.rsmjournals.com/ ↗
http://ebm.sagepub.com/ ↗
http://www.ebmonline.org ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/1535370216632623 ↗
- Languages:
- English
- ISSNs:
- 1535-3702
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 6646.xml